Kolexia
Coeffic David Oncologie médicale
Coeffic David
Oncologie médicale
Selarl Institut De Cancerologie De Provence
Aix-en-Provence, France
69 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Métastase lymphatique Hypertension artérielle Carcinome canalaire du sein Nausée Vomissement

Collaborateurs

Voir plus
Prulhiere-Corviole Karinne
Prulhiere-Corviole Karinne
Polyclinique De Courlancy, Reims, France
Eymard Jean-Christophe
Eymard Jean-Christophe
Institut Godinot, Reims, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Mouysset Jean-Loup
Mouysset Jean-Loup
Polyclin Parc Rambot Hop Priv Provence, Aix-en-Provence, France

Industries

Voir plus
A+A
28 collaboration(s)
Dernière en 2023
B3TSI
17 collaboration(s)
Dernière en 2023
MSD
9 collaboration(s)
Dernière en 2023
Pfizer
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Anticancer research   27 janvier 2023
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Essai Clinique (Roche)   05 mai 2022
Identification of Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer by Fourier-Transform Infrared Micro-Imaging.
Cancers   21 décembre 2021
PCN269 Patients and Healthcare Providers Reported Outcomes of an E-Health System (ZEMY) Designed to Manage Symptoms and Treatment-Related Toxicities in Patients with Breast Cancer
Virtual ISPOR Europe 2020   01 décembre 2020
PCN235 Feasibility Assessment of an E-Health System (ZEMY) Designed to Manage Symptoms and Treatment-Related Toxicities in Patients with Breast Cancer
Virtual ISPOR Europe 2020   01 décembre 2020
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
EClinicalMedicine   04 novembre 2020
823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer.
Bulletin du cancer   10 juin 2020
Interventional multicenter study to assess the feasibility of an e-health system (ZEMY) designed to manage symptoms and treatment-related toxicities in patients with breast cancer.
2020 ASCO Annual Meeting I   25 mai 2020
KALICOU3: Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Essai Clinique (Centre Oscar-Lambret)   24 juin 2019